Table 1 Patient characteristics of entire cohort.
Characteristics | N | No. of patients (%) |
|---|---|---|
Age (59.1,31–78) | ||
<60 | 35 | 52.2 |
≥ 60 | 32 | 47.8 |
Gender | ||
Male | 31 | 46.3 |
Female | 36 | 53.7 |
ECOG status | ||
0–1 | 63 | 94 |
2 | 4 | 6 |
Histology | ||
Adenocarcinoma | 67 | 100 |
EGFR mutation | ||
Exon19 deletion | 26 | 38.8 |
Exon 21 L858R | 32 | 47.8 |
Exon 18 | 5 | 7.5 |
Exon 20 | 4 | 6 |
Smoking status | ||
Yes | 28 | 41.8 |
No | 39 | 58.2 |
T stage | ||
1–2 | 37 | 55.2 |
3–4 | 30 | 44.8 |
N stage | ||
0–1 | 8 | 11.9 |
2–3 | 59 | 88.1 |
M stage | ||
Yes | 46 | 68.7 |
No | 21 | 31.3 |
No. of metastases | ||
0 | 21 | 31.3 |
1–2 | 27 | 40.3 |
3–5 | 19 | 28.4 |
Metastasis location | ||
Brain | 16 | 23.9 |
Bone | 21 | 31.3 |
Adrenal | 4 | 6 |
Liver | 3 | 4.5 |
Pleura | 8 | 11.9 |
No-regional lymph nodes | 5 | 7.5 |
Radiotherapy site | ||
Lung | 49 | 74.2 |
Bone | 10 | 15.2 |
Brain | 10 | 15.2 |
TRP | ||
1–2 grades | 4 | 6 |
≥ 3 grades | 1 | 1.5 |
TKI drugs | ||
First generation | 38 | 56.7 |
Second generation | 12 | 17.9 |
Third generation | 17 | 25.4 |
Initial chemotherapy | ||
Yes | 32 | 47.8 |
No | 35 | 52.2 |
Definitive or Palliative chemotherapy | ||
Definitive | 11 | 16.4 |
Palliative | 21 | 31.3 |
Patterns of progression | ||
Local progression | 52 | 77.60% |
Distant metastasis | 12 | 17.90% |
Progress of distant metastases | 3 | 4.50% |
